Latest Breaking News On - Lewis co glass - Page 1 : comparemela.com

ISS and Glass Lewis Update 2024 Proxy Voting Guidelines

Explore key updates for the 2024 proxy season from Glass Lewis and ISS impacting Canadian public companies. This article delves into the significant changes in policies related to executive compensation, board diversity, climate risk, cyber risk oversight, and more. These updates are crucial for companies to align their governance and disclosure practices with the latest recommendations to avoid potential adverse voting recommendations. Learn about these vital changes and their implications for your business.

Adam weryhaJohn piastaCorporate governance committee performanceTask force on financial disclosuresLewis co glassInstitutional shareholder servicesCommittee performanceWritten by john piastaKris hancGlass lewisGlass lewiTask forceClimate related financial disclosuresSustainability accounting standards boardCompensation discussionEquity awards

ISS and Glass Lewis Update 2024 Proxy Voting Guidelines | Bennett Jones LLP

Glass, Lewis & Co (Glass Lewis) and Institutional Shareholder Services (ISS) have each released updates to their Canadian proxy voting guidelines for the 2024 proxy season. The Glass.

Bennett jonesLewis co glassInstitutional shareholder servicesCorporate governance committee performanceTask force on financial disclosuresCommittee performanceGlass lewisGlass lewiTask forceClimate related financial disclosuresSustainability accounting standards boardCompensation discussionEquity awardsCorporate governanceCorporate governance committeeGovernance committee

Proxy advisory firms throw weight behind Newmont s Newcrest deal

Proxy advisory firms throw weight behind Newmont s Newcrest deal
miningweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miningweekly.com Daily Mail and Mail on Sunday newspapers.

Institutional shareholder servicesLewis co glassGlass lewis

Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab in Patients with Squamous Cell Cancer of the Head and Neck

CAMBRIDGE - Infinity Pharmaceuticals, Inc. , a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced.

United kingdomEzra cohenRobert ilariaMelissa hackelInfinity pharmaceuticals incMorrow sodaliClinical programPharma incInfinity pharmaceuticalsInstitutional shareholder services incLewis co glassDrug administrationChief medicalInfinity chief medical officerInfinity mergerClinical program update

Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN)

CAMBRIDGE, Mass. (BUSINESS WIRE) Jul 10, 2023

United statesUnited kingdomEzra cohenRobert ilariaMelissa hackelExchange commissionClinical program updateInstitutional shareholder services incMorrow sodaliDrug administrationInfinity pharmaceuticalsPharma incInfinity pharmaceuticals incLewis co glassChief medicalInfinity chief medical officer robert ilaria